Abstract
Purpose: To evaluate safety in an interim analysis of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in 13 patients with hepatic metastases from neuroendocrine tumors (NETs) as part of a phase II trial. Methods: Institutional Review Board approval and informed consent were obtained. Thirteen patients completed preliminary safety analysis. Their mean age was 65 years, Eastern Cooperative Oncology Group status was 0/1, tumor burden range was 4-75 %, and mean targeted tumor size was 5.9 cm. Up to four DEB-TACE sessions (100-300 μm beads loaded with ≤100 mg doxorubicin) within 6 months were allowed. Tumor response was assessed by magnetic resonance imaging 1 month after treatment using contrast-enhancement [European Association for the Study of the Liver (EASL) and size Response Evaluation Criteria in Solid Tumors (RECIST)] criteria. Safety was assessed by National Cancer Institute Common Terminology Criteria. Results:: DEB-TACE was successfully performed in all 13 patients. At 1 month follow-up, there was a mean 12 % decrease in tumor size (p <0.0003) and a 56 % decrease in tumor enhancement (p <0.0001). By EASL criteria, the targeted lesion objective response rate was 78 %. Grade 3 to 4 toxicities were fatigue (23 %), increased alanine amino transferase (15 %), hyperglycemia (15 %), and abdominal pain (8 %). Seven patients developed bilomas (54 %); all of these patients had multiple small (
| Original language | English (US) |
|---|---|
| Pages (from-to) | 449-459 |
| Number of pages | 11 |
| Journal | CardioVascular and Interventional Radiology |
| Volume | 36 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2013 |
Fingerprint
Keywords
- Biliary injury
- Chemoembolization
- Drug-eluting beads
- Neuroendocrine metastases
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Cite this
Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases : High incidence of biliary injury. / Bhagat, Nikhil; Reyes, Diane K.; Lin, Mingde; Kamel, Ihab R; Pawlik, Timothy M.; Frangakis, Constantine; Geschwind, J. F.
In: CardioVascular and Interventional Radiology, Vol. 36, No. 2, 04.2013, p. 449-459.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases
T2 - High incidence of biliary injury
AU - Bhagat, Nikhil
AU - Reyes, Diane K.
AU - Lin, Mingde
AU - Kamel, Ihab R
AU - Pawlik, Timothy M.
AU - Frangakis, Constantine
AU - Geschwind, J. F.
PY - 2013/4
Y1 - 2013/4
N2 - Purpose: To evaluate safety in an interim analysis of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in 13 patients with hepatic metastases from neuroendocrine tumors (NETs) as part of a phase II trial. Methods: Institutional Review Board approval and informed consent were obtained. Thirteen patients completed preliminary safety analysis. Their mean age was 65 years, Eastern Cooperative Oncology Group status was 0/1, tumor burden range was 4-75 %, and mean targeted tumor size was 5.9 cm. Up to four DEB-TACE sessions (100-300 μm beads loaded with ≤100 mg doxorubicin) within 6 months were allowed. Tumor response was assessed by magnetic resonance imaging 1 month after treatment using contrast-enhancement [European Association for the Study of the Liver (EASL) and size Response Evaluation Criteria in Solid Tumors (RECIST)] criteria. Safety was assessed by National Cancer Institute Common Terminology Criteria. Results:: DEB-TACE was successfully performed in all 13 patients. At 1 month follow-up, there was a mean 12 % decrease in tumor size (p <0.0003) and a 56 % decrease in tumor enhancement (p <0.0001). By EASL criteria, the targeted lesion objective response rate was 78 %. Grade 3 to 4 toxicities were fatigue (23 %), increased alanine amino transferase (15 %), hyperglycemia (15 %), and abdominal pain (8 %). Seven patients developed bilomas (54 %); all of these patients had multiple small (
AB - Purpose: To evaluate safety in an interim analysis of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in 13 patients with hepatic metastases from neuroendocrine tumors (NETs) as part of a phase II trial. Methods: Institutional Review Board approval and informed consent were obtained. Thirteen patients completed preliminary safety analysis. Their mean age was 65 years, Eastern Cooperative Oncology Group status was 0/1, tumor burden range was 4-75 %, and mean targeted tumor size was 5.9 cm. Up to four DEB-TACE sessions (100-300 μm beads loaded with ≤100 mg doxorubicin) within 6 months were allowed. Tumor response was assessed by magnetic resonance imaging 1 month after treatment using contrast-enhancement [European Association for the Study of the Liver (EASL) and size Response Evaluation Criteria in Solid Tumors (RECIST)] criteria. Safety was assessed by National Cancer Institute Common Terminology Criteria. Results:: DEB-TACE was successfully performed in all 13 patients. At 1 month follow-up, there was a mean 12 % decrease in tumor size (p <0.0003) and a 56 % decrease in tumor enhancement (p <0.0001). By EASL criteria, the targeted lesion objective response rate was 78 %. Grade 3 to 4 toxicities were fatigue (23 %), increased alanine amino transferase (15 %), hyperglycemia (15 %), and abdominal pain (8 %). Seven patients developed bilomas (54 %); all of these patients had multiple small (
KW - Biliary injury
KW - Chemoembolization
KW - Drug-eluting beads
KW - Neuroendocrine metastases
UR - http://www.scopus.com/inward/record.url?scp=84875223168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875223168&partnerID=8YFLogxK
U2 - 10.1007/s00270-012-0424-y
DO - 10.1007/s00270-012-0424-y
M3 - Article
C2 - 22722717
AN - SCOPUS:84875223168
VL - 36
SP - 449
EP - 459
JO - CardioVascular and Interventional Radiology
JF - CardioVascular and Interventional Radiology
SN - 7415-5101
IS - 2
ER -